<DOC>
	<DOCNO>NCT01075698</DOCNO>
	<brief_summary>The present research conduct randomize , parallel-group , control , open study ( use PROBE method ) primarily verify effect various biomarkers high-risk hypertensive patient treat ARB ( telmisartan , ARB group ) compare patient receive ordinary therapy ( non-ARB group ( ordinary therapy group ) ) . In addition , onset cardiovascular event level marker associate cardiovascular event observe time examine significance marker . The biomarkers obtain start study ( registration ) , 6 , 12 , 24 36 month start study .</brief_summary>
	<brief_title>A Trial Telmisartan Prevention Cardiovascular Disease</brief_title>
	<detailed_description>Events define follow ; Cerebrovascular event : Stroke ( cerebral infarction , cerebral hemorrhage , subarachnoid hemorrhage , unknown type stroke ) , transient ischemic attack Coronary event : Myocardial infarction , angina pectoris , asymptomatic myocardial ischemia Cardiac event : Myocardial infarction , angina pectoris , asymptomatic myocardial ischemia , heart failure Aortic/peripheral arterial event : Aortic aneurysm , aortic dissection , arteriosclerotic disease ( aorta , carotid artery , renal artery , mesenteric artery , peripheral artery , etc . ) Complications diabetes : Diabetic nephropathy* , diabetic retinopathy* , diabetic neuropathy* Aggravation renal function : Doubling serum creatinine level , ESRD ( initiation dialysis , renal transplantation ) *Newly occur aggravate The following measure biomarkers ; urinary albumin creatinine rate ( UACR ) , plasma brain natriuretic peptide ( BNP ) , urinary 8-hydroxy-deoxy-guanosine ( 8-OHdG ) , serum adiponectin , serum high-molecular weight adiponectin , high sensitivity c-reactive protein ( hsCRP ) , estimate glomerular filtration rate ( eGFR )</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Patients meet criterion list [ 1 ] [ 4 ] least one cardiovascular risk list [ 1 ] [ 5 ] include study . 1 . Outpatients 2 . Age : ≥ 40 &lt; 80 3 . Hypertension : Systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg two late measurement casual blood pressure ( sit position ) regardless treat untreated condition , systolic blood pressure &lt; 140 mmHg diastolic blood pressure &lt; 90 mmHg require antihypertensive treatment . Assessment hypertension : Blood pressure measure least twice interval 1 2 minute . If measure value obtain substantially different , additional measurement perform average two stable measurement use assessment . 4 . Patients give consent participate present study . Cardiovascular risk : 1 . Diabetes mellitus ; Type 2 diabetes mellitus 2 . Kidney ; Serum creatinine : 1.2 mg/dL &lt; 2.0 mg/dL male , 1.0 mg/dL &lt; 2.0 mg/dL female Proteinuria : qualitative value ≥ +1 ( quantitative value : proteinuria value ≥ 0.3 g/g・Cr casual urine adjust urine creatinine ) CKD stage 3 high ( GFR &lt; 60 mL/min/1.73 m2 ) 3 . Heart ; Previous myocardial infarction note 6 month obtain informed consent Diagnosis angina pectoris Diagnosis heart failure ( NYHA I II class ) Diagnosis leave ventricular hypertrophy ( left ventricular posterior wall ≥ 12 mm evidence echocardiography perform prior obtain inform consent , Sv1+Rv5 ≥ 35 mm note ECG find ) Diagnosis transient persist atrial fibrillation 4 . Brain ; Previous cerebral infarction , cerebral hemorrhage , subarachnoid hemorrhage transient cerebral ischemic attack note 6 month obtain informed consent 5 . Peripheral arterial disease ; Previous lowerlimb bypass surgery angioplasty perform 6 month obtain informed consent Anklebrachial pressure index &lt; 0.9 intermittent claudication Patients meet follow criterion exclude study . 1 . Type 1 diabetes mellitus 2 . Severe renal disorder ( serum creatinine ≥ 2.0 mg/dL ) 3 . Myocardial infarction , percutaneous transluminal angioplasty bypass surgery coronary artery/ lowerlimb blood vessel , cerebral infarction , cerebral hemorrhage , subarachnoid hemorrhage transient cerebral ischemic attack note within 6 month initiation observation 4 . Diagnosis heart failure ( NYHA III IV class ) 5 . Virulent hypertension secondary hypertension 6 . Pregnant woman 7 . Clinically relevant allergic symptom past history hypersensitivity drug / significant adverse drug reaction 8 . Extremely poor bile secretion serious liver disorder 9 . Treatmentrequired malignant tumor 10 . Patients judge physician charge ineligible study reason</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Cerebrovascular disease</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Peripheral Artery Disease</keyword>
</DOC>